CSIMarket
 
Genenta Science S p a   (GNTA)
Other Ticker:  
 
 
Price: $3.9000 $-0.10 -2.500%
Day's High: $3.9 Week Perf: -1.81 %
Day's Low: $ 3.90 30 Day Perf: 20 %
Volume (M): 0 52 Wk High: $ 6.81
Volume (M$): $ 1 52 Wk Avg: $5.29
Open: $3.90 52 Wk Low: $3.11



 Market Capitalization (Millions $) 71
 Shares Outstanding (Millions) 18
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Genenta Science S P A
Genenta Science S.p.A. is a biotechnology company based in Milan, Italy. The company specializes in developing innovative gene therapies to treat various types of cancer. Genenta Science focuses on using a unique approach called Immune Reprogramming Gene Therapy (IRGT) to modify the patient's immune cells for targeted cancer treatment. IRGT involves modifying hematopoietic stem cells and reprogramming them to express specific genes that activate the immune system against cancer cells. This approach aims to enhance the body's ability to fight cancer and potentially offer new treatment options for patients. Genenta Science is dedicated to advancing the field of gene therapy and improving the lives of cancer patients.


   Company Address: Via Olgettina No. 58 Milan 20132
   Company Phone Number: 02-2643-4681   Stock Exchange / Ticker: NASDAQ GNTA
   GNTA is expected to report next financial results on April 20, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Genenta's Groundbreaking Reprogramming of Tumor Microenvironment Sets a New Course for Innovative Solid Tumor Treatments

Published Thu, Feb 8 2024 10:00 AM UTC

In recent years, scientific advancements in cancer treatment have focused on exploring innovative therapies that target the tumor microenvironment (TME), the complex network of cells and molecules surrounding the tumor. Genenta, a pioneering biopharmaceutical company, has recently demonstrated remarkable progress in reprogramming the TME in patients with glioblastoma multifo...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com